The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein ...

As research becomes ever more sophisticated and regulatory requirements tighten, ProPure ™ is a game-changer for life science ...

From now to Dec 31st, 2025, we’re offering a free pilot trail on HTP antibody production for new clients to accelerate your ...

Normally, Tau proteins stabilize microtubules and support neuronal function, but in neurodegenerative diseases such as ...

Recent developments in protein engineering technologies, such as cell-free methods, have brought the field into a golden era of innovation, creating new opportunities and ingenious products that can ...

Pichia pastoris has emerged as a central microbial host for recombinant protein production, offering a unique balance of rapid growth, capacity for post‐translational modifications, and ease of ...

Sometimes recombinant strains revert to their wild nature even after 13 generations of propagation.” Formulation is another very costly part of vaccine production. notes Uma, “The stability of ...

Recombinant protein vaccines, which are obtained by conventional genetic engineering, are based on the proteins of target pathogens that can activate our immune systems. Unlike other types of vaccines ...

The history of antibody engineering and production in drug discovery can be traced back to the 1970s and 1980s [1] when scientists first began to explore the potential of using antibodies as ...

Inclusion bodies, once considered a hindrance in recombinant protein production, are now recognised for their potential as reservoirs of bioactive proteins and functional biomaterials. In bacterial ...

It takes a lot of infrastructure, and money, to build the giant bioreactors experts say are needed to mass produce raw materials to make things like medicine, vaccines and cultivated meat. Matt ...

Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, and Protalix BioTherapeutics, Inc.